MA27169A1 - Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique - Google Patents

Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique

Info

Publication number
MA27169A1
MA27169A1 MA27796A MA27796A MA27169A1 MA 27169 A1 MA27169 A1 MA 27169A1 MA 27796 A MA27796 A MA 27796A MA 27796 A MA27796 A MA 27796A MA 27169 A1 MA27169 A1 MA 27169A1
Authority
MA
Morocco
Prior art keywords
tertiobutylbenzyl
sulfonyl
phenoxy
pyridine
amino
Prior art date
Application number
MA27796A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Kim Anne Johnson
Bruce Allen Lefker
Chandra Aggarwal Prakash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27169A1 publication Critical patent/MA27169A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 31 Janvier 2002 60/353,748 Voir en annexe le titre de l'invention et le texte de l'abrégé Métabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-méthyl}-phénoxy)-acétique La présente invention concerne des métabolites de l'acide (3-{ [4-tertiobutylbenzyl) - (pyridine-3-sulfonyl) - amino]-méthyl}-phénoxy)-acétique.
MA27796A 2002-01-31 2004-07-21 Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique MA27169A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
MA27169A1 true MA27169A1 (fr) 2005-01-03

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27796A MA27169A1 (fr) 2002-01-31 2004-07-21 Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique

Country Status (30)

Country Link
US (1) US6852863B2 (fr)
EP (1) EP1470109A1 (fr)
JP (1) JP2005521668A (fr)
KR (1) KR20040077884A (fr)
CN (1) CN1625549A (fr)
AP (1) AP2004003094A0 (fr)
AR (1) AR038332A1 (fr)
BR (1) BR0307339A (fr)
CA (1) CA2473984A1 (fr)
EA (1) EA200400724A1 (fr)
EC (1) ECSP045215A (fr)
GB (1) GB2400100B (fr)
HN (1) HN2003000051A (fr)
HR (1) HRP20040683A2 (fr)
HU (1) HUP0500012A2 (fr)
IL (1) IL162167A0 (fr)
IS (1) IS7281A (fr)
MA (1) MA27169A1 (fr)
MX (1) MXPA04004960A (fr)
NO (1) NO20043569D0 (fr)
OA (1) OA12760A (fr)
PA (1) PA8564601A1 (fr)
PE (1) PE20030978A1 (fr)
PL (1) PL371982A1 (fr)
PY (1) PY0300568A (fr)
TN (1) TNSN04138A1 (fr)
TW (1) TW200302080A (fr)
UY (1) UY27632A1 (fr)
WO (1) WO2003064391A1 (fr)
ZA (1) ZA200404067B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7666330B2 (en) * 2005-04-20 2010-02-23 Lg Chem, Ltd. Additive for non-aqueous electrolyte and secondary battery using the same
AU2007280130B2 (en) * 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
EP2126574B1 (fr) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Modulateurs de l'aldéhyde deshydrogènase-2 mitochondrial, et leurs procédés d'utilisation
EP2002834A1 (fr) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryle/hétarylamides en tant que modulateurs du récepteur EP2
SI2264009T1 (sl) * 2008-03-12 2019-05-31 Ube Industries, Ltd. Spojina piridilaminoocetne kisline
EP2149551A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2
EP2149554A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamides en tant que modulateurs du récepteur EP2
EP2149552A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2
WO2010028175A1 (fr) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulateurs de l'activité de l'aldéhyde déshydrogénase et leurs procédés d'utilisation
EP2349279A4 (fr) 2008-10-28 2013-12-25 Univ Leland Stanford Junior Modulateurs d'aldéhyde déshydrogénase et procédés d'utilisation de ceux-ci
HUE026742T2 (en) 2009-03-30 2016-07-28 Ube Industries A pharmaceutical composition for the treatment or prevention of glaucoma
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2012149106A1 (fr) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procédés d'augmentation de la prolifération de cellules souches salivaires adultes
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
TNSN04138A1 (fr) 2007-03-12
IS7281A (is) 2004-05-21
NO20043569L (no) 2004-08-26
AR038332A1 (es) 2005-01-12
PL371982A1 (en) 2005-07-11
BR0307339A (pt) 2004-12-07
AP2004003094A0 (en) 2004-09-30
US6852863B2 (en) 2005-02-08
IL162167A0 (en) 2005-11-20
GB0413967D0 (en) 2004-07-28
UY27632A1 (es) 2003-08-29
GB2400100B (en) 2006-04-12
EP1470109A1 (fr) 2004-10-27
HRP20040683A2 (en) 2004-10-31
TW200302080A (en) 2003-08-01
GB2400100A (en) 2004-10-06
HN2003000051A (es) 2003-09-24
JP2005521668A (ja) 2005-07-21
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (fr) 2003-08-07
HUP0500012A2 (hu) 2005-04-28
ZA200404067B (en) 2005-08-29
EA200400724A1 (ru) 2004-12-30
CN1625549A (zh) 2005-06-08
ECSP045215A (es) 2004-09-28
US20030216445A1 (en) 2003-11-20
OA12760A (en) 2006-07-04
NO20043569D0 (no) 2004-08-26
MXPA04004960A (es) 2005-04-08
CA2473984A1 (fr) 2003-08-07
PE20030978A1 (es) 2003-11-19
PY0300568A (es) 2004-10-01
PA8564601A1 (es) 2003-09-05

Similar Documents

Publication Publication Date Title
MA27169A1 (fr) Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
AP2001002217A0 (fr) Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
MA28303A1 (fr) Derives de sulfonamides pour le traitement de maladies
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
AP2002002637A0 (en) Novel piperazine
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
BR9900443A (pt) Esteres de ácido aril acrìlico.
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
CY1109055T1 (el) 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
GB0111186D0 (en) Novel compounds
MXPA02011370A (es) Iminoazinas substituidas.
MA30042B1 (fr) Composes calcilytiques
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ZA200404475B (en) Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof.
MY133969A (en) Indoloquinazolinones
SE9901077D0 (sv) Novel use
TW200500348A (en) Biguanide and dihydrotriazine derivatives
ATE433966T1 (de) Methylendipiperidinderivate
MA27059A1 (fr) Azithromycine en dose unique
GB0320320D0 (en) Novel compounds
GB0322510D0 (en) Novel compounds
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
EA200401289A1 (ru) Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.